Jubilant Life Sciences has received approval to form a committee to explore options and opportunities to raise debt for the Company. The committee will decide the ways to raise debt including issue of foreign currency bonds and /or non-convertible debentures, or by any one or more or a combination of the above or otherwise, to be denominated in Indian rupees or foreign currency, as the case may be, to various eligible investors in or outside India, whether by way of a public offering or by way of a private placement.
The company has decided to raise debt up to an amount not exceeding $ 250 million for prepayment of the existing debt and other general corporate purposes without increasing the overall net debt levels of the Company.
Jubilant Life Sciences is an integrated Pharmaceuticals and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution provider out of India.
